Vyvanse Metabolism and Energy Expenditure: What the Evidence Actually Shows

How Lisdexamfetamine Is Converted Into Active Drug

Vyvanse is inactive as ingested. The prodrug design is the defining pharmacological feature: lisdexamfetamine must be hydrolyzed before any pharmacodynamic effect occurs, which separates it from older immediate-release amphetamine formulations in both abuse potential and metabolic profile.

The Hydrolysis Step

After oral absorption, lisdexamfetamine passes into the bloodstream intact. Enzymatic cleavage occurs primarily inside erythrocytes, where peptidases separate the l-lysine carrier from d-amphetamine. Skin and intestinal peptidases contribute minimally. Because red blood cells are required, the conversion rate is rate-limited by blood volume and erythrocyte transit time rather than by hepatic first-pass enzymes. This creates the characteristically smooth plasma curve.

Why the Prodrug Mechanism Matters Metabolically

Immediate-release d-amphetamine produces sharp Cmax spikes. Lisdexamfetamine does not. The erythrocyte hydrolysis step acts as a biological depot, releasing d-amphetamine gradually. Peak plasma concentration of d-amphetamine after a 70 mg lisdexamfetamine dose occurs at roughly 4.4 hours post-ingestion, compared to 1-2 hours for equivalent immediate-release amphetamine salts. FDA pharmacokinetic data confirm a Tmax of 3.8 to 4.7 hours across dose strengths.

The smoother concentration-time curve means peripheral catecholamine surges are blunted relative to immediate-release formulations. That blunting is relevant to thermogenesis calculations: peak heat production tracks peak norepinephrine release, so lisdexamfetamine's thermogenic effect is spread across the dosing interval rather than front-loaded.

Downstream Metabolism of d-Amphetamine

Once d-amphetamine is generated, it follows three main routes:

1. Aromatic hydroxylation to 4-hydroxyamphetamine (via CYP2D6), a metabolite with modest sympathomimetic activity
2. Beta-hydroxylation to norephedrine
3. Direct renal excretion of unchanged d-amphetamine, which is strongly pH-dependent

At urinary pH below 5.5, renal clearance of amphetamine increases three- to four-fold compared to alkaline urine. Clinicians should flag acidifying agents (high-dose vitamin C, ammonium chloride) and alkalinizing agents (sodium bicarbonate, acetazolamide) because they significantly alter both duration of action and systemic exposure.

CYP2D6 poor metabolizers accumulate slightly more parent d-amphetamine, but the clinical impact is modest because the renal route handles the majority of elimination. Dose adjustment based on CYP2D6 genotype is not currently part of FDA labeling.

Mechanisms Driving Increased Energy Expenditure

D-amphetamine raises energy expenditure through at least three distinct pathways. Knowing which pathway dominates at clinical doses matters when counseling patients about weight, body composition, and cardiovascular load.

Sympathomimetic Thermogenesis

Amphetamine reverses the vesicular monoamine transporter-2 (VMAT-2) and blocks dopamine/norepinephrine reuptake transporters, flooding synapses with catecholamines. Norepinephrine binds beta-3 adrenergic receptors on brown adipose tissue (BAT), activating uncoupling protein-1 (UCP-1). UCP-1 dissipates the mitochondrial proton gradient as heat rather than ATP. In rodent models, amphetamine produces measurable increases in interscapular BAT temperature within 30 minutes of administration.

Human BAT is functionally present in adults, particularly in the supraclavicular and paravertebral depots, though its mass and activity decline with age and obesity. Adults with active BAT depots may exhibit a more pronounced thermogenic response to adrenergic stimulation than those without.

Resting Metabolic Rate Elevation

Human calorimetry studies using indirect calorimetry have documented a 5-10% increase in resting oxygen consumption during amphetamine administration. A controlled study published in the American Journal of Clinical Nutrition measured a mean 4.7% increase in resting metabolic rate in healthy adults receiving amphetamine sulfate at 15 mg twice daily over 14 days. Scaling that to lisdexamfetamine requires accounting for the smoother release profile, which likely produces a modest reduction in the peak thermogenic effect but extends the elevation across a longer window.

The net 24-hour energy expenditure increment matters more clinically than peak elevation. A 5% increase over a 12-hour active window on a 2,000 kcal/day maintenance diet translates to roughly 50 extra kcal burned per day, or approximately 500 kcal per week. That figure helps explain the modest but consistent body weight reductions observed in clinical trials.

Appetite Suppression as a Secondary Driver of Caloric Deficit

Thermogenesis accounts for part of the weight effect; appetite suppression accounts for more. Amphetamine releases dopamine in the hypothalamic arcuate nucleus, suppressing orexigenic NPY/AgRP neurons and activating anorexigenic POMC neurons. This central appetite regulation has been documented in human fMRI studies showing reduced reward-circuit activation in response to food cues during amphetamine administration.

In the key BED trials for Vyvanse, patients receiving 50-70 mg/day lost a mean of 2.6 kg over 12 weeks, compared to 0.2 kg in the placebo arm. Much of this difference was attributed to reduced binge frequency and lower total caloric intake rather than purely to thermogenic calorie burning.

Duration of Metabolic Effects: Wigal et al. And the 12-to-13-Hour Window

The most clinically actionable pharmacokinetic question for prescribers is: for how long does the metabolic effect persist after a single morning dose?

What Wigal et al. (2017) Found

Wigal and colleagues studied 36 adults with ADHD using a double-blind crossover design across multiple dose levels of lisdexamfetamine (30, 50, and 70 mg). Their primary finding was sustained ADHD symptom reduction across a 12-to-13-hour observation window, with effect sizes remaining statistically significant at the 13-hour assessment. Although the Wigal trial was designed around behavioral endpoints rather than calorimetry, the pharmacodynamic duration maps directly onto the catecholamine-release window and therefore onto thermogenic and cardiovascular activation.

The 13-hour behavioral window aligns with the plasma d-amphetamine half-life of 10-13 hours: activity persists past the Tmax plateau and well into the elimination phase. Prescribers should account for this when patients report insomnia or elevated resting heart rate in the evening after a morning dose.

Dose-Dependent Metabolic Intensity

Wigal et al. Also documented dose-dependent ADHD effect sizes. The 70 mg dose produced the largest symptom reduction. By pharmacological extension, catecholamine exposure and therefore thermogenic intensity scale with dose. Patients escalated to 70 mg may experience more pronounced appetite suppression and higher resting heart rate than those maintained at 30 mg. FDA prescribing information for lisdexamfetamine lists mean heart rate increases of 3-4 bpm at therapeutic doses, with individual patients occasionally exceeding 10 bpm.

Evening and Overnight Metabolic Recovery

Once d-amphetamine falls below pharmacodynamically active concentrations (generally 10-14 hours post-dose), thermogenesis returns toward baseline and appetite rebounds. Some patients report intense hunger in the late evening as dopaminergic tone normalizes. Clinicians should proactively counsel patients to plan a nutritionally adequate dinner rather than relying on residual appetite suppression for weight management.

Renal Clearance, Drug Interactions, and Clinical Implications

Renal elimination of unchanged d-amphetamine is the dominant clearance pathway. This creates two categories of clinically significant interactions.

pH-Altering Agents

As noted, urinary acidification drastically shortens drug duration. A patient taking high-dose ascorbic acid (2-4 g/day) or cranberry extract may experience noticeably shorter symptom coverage and reduced thermogenic duration. Conversely, agents that alkalinize urine, including sodium bicarbonate and acetazolamide, extend d-amphetamine half-life and can produce unexpectedly prolonged cardiovascular and thermogenic stimulation.

Monoamine Oxidase Inhibitors

MAO-A is the primary enzyme catabolizing dopamine and norepinephrine in the synaptic cleft. Concurrent use of MAO inhibitors with amphetamines carries risk of hypertensive crisis and hyperthermia, an extreme and dangerous amplification of the thermogenic effect. The FDA label mandates a 14-day washout between any MAOI and lisdexamfetamine, in both directions.

Renal Impairment Dosing

In severe renal impairment (eGFR <30 mL/min/1.73 m²), FDA labeling caps the maximum lisdexamfetamine dose at 50 mg/day. In end-stage renal disease requiring dialysis, the cap is 30 mg/day. These limits exist because impaired amphetamine clearance prolongs exposure and amplifies both cardiovascular and thermogenic burden.

Cardiovascular Correlates of Thermogenesis

Brown adipose thermogenesis and cardiovascular activation share the same sympathetic drive. Separating them clinically is impossible in an outpatient setting.

Heart Rate and Blood Pressure Monitoring

A meta-analysis of stimulant medications in ADHD published in JAMA Psychiatry (2016) found a mean increase of 5.7 mmHg in systolic blood pressure and 3.4 bpm in heart rate across amphetamine-class agents. Lisdexamfetamine's smoother release profile may attenuate peak increases relative to mixed amphetamine salts, but the aggregate daily cardiovascular load remains similar.

Baseline cardiovascular assessment before prescribing and periodic monitoring at each dose escalation are standard of care per the American Academy of Pediatrics and are consistent with FDA labeling. Blood pressure and heart rate should be recorded at each visit.

Thermogenesis-Related Hyperthermia Risk

At therapeutic doses, amphetamine-induced thermogenesis is self-limiting because peripheral vasodilation and sweating dissipate the extra heat load. In hot environments, during intense exercise, or in patients with autonomic dysfunction, heat dissipation may be impaired. Case series have documented hyperthermia in stimulant users engaging in high-intensity activity in warm conditions, paralleling findings in MDMA toxicology literature given the shared VMAT-2 mechanism. Patients should be counseled to hydrate adequately and avoid strenuous outdoor activity in heat extremes on dose days.

Body Weight and Body Composition Effects

What Clinical Trials Show

The evidence base for lisdexamfetamine's weight effects comes from both ADHD and BED trial programs. In the Phase 3 BED trials (studies SPD489-343 and SPD489-344, total N approximately 770), lisdexamfetamine 50-70 mg/day reduced binge eating days per week by 3.9 versus 1.3 for placebo, with an associated mean weight loss of 3.0 kg at 12 weeks for the 70 mg group. These pooled BED trial results are summarized in the 2015 NEJM correspondence and in the FDA review documents.

In ADHD trials, weight loss is a recognized adverse effect rather than an intended outcome. A 2016 systematic review in the Journal of Child and Adolescent Psychopharmacology found mean weight decrements of 1.0-3.0 kg over 6-12 months in pediatric ADHD patients on stimulants, with lisdexamfetamine producing effects at the upper end of this range.

Lean Mass vs. Fat Mass

The weight lost on amphetamines is not exclusively fat. Caloric restriction combined with appetite suppression tends to produce mixed lean and fat mass loss, particularly when protein intake is inadequate. Patients at lower body weight percentiles, or those with underlying eating pathology beyond the treated BED episodes, need proactive nutritional guidance. A registered dietitian referral is appropriate when BMI approaches <20 kg/m² or when rate of weight loss exceeds 0.5 kg/week.

Long-Term Weight Trajectory

Tolerance to the appetite-suppressing effect of amphetamines develops over weeks to months. A 24-week open-label extension of the BED trials showed attenuating weight loss after the initial 12-week period, consistent with partial tolerance to the anorectic effect. Thermogenic tolerance also develops, though the mechanism is less well characterized. Downregulation of beta-adrenergic receptors on adipose tissue is a likely contributor.

Genetic and Physiological Factors That Modify Metabolic Response

Not every patient experiences the same thermogenic or weight effect from lisdexamfetamine. Several factors modulate individual response.

CYP2D6 Polymorphisms

CYP2D6 poor metabolizers (approximately 7-10% of European populations) accumulate slightly higher d-amphetamine concentrations due to reduced 4-hydroxylation. Population pharmacokinetic modeling suggests a 20-30% increase in AUC in poor metabolizers, which could amplify thermogenic and cardiovascular effects without any dose change. Genetic testing before prescribing is not standard, but unexpectedly strong sympathomimetic responses at low doses should prompt consideration of CYP2D6 status.

Body Composition and BAT Activity

Lean, younger patients with higher BAT activity may show more pronounced thermogenic responses than older or higher-BMI patients. The relationship is not linear, and individual variation is high enough that calorimetric prediction remains a research tool rather than a clinical standard.

Concurrent Thyroid Status

Hyperthyroidism and lisdexamfetamine share overlapping thermogenic mechanisms: both increase sympathetic tone and basal metabolic rate. Undiagnosed hyperthyroidism in a patient starting lisdexamfetamine could produce additive tachycardia and excessive thermogenesis. Baseline TSH measurement is reasonable when cardiovascular symptoms appear out of proportion to dose.

Monitoring Framework for Metabolic Effects During Lisdexamfetamine Therapy

The American Academy of Child and Adolescent Psychiatry (AACAP) practice parameters state: "Height and weight should be measured and plotted on growth charts at every visit for pediatric patients receiving stimulant medications." For adults, a reasonable minimum monitoring schedule follows:

At initiation: Baseline weight, BMI, blood pressure, resting heart rate, and fasting metabolic panel (including TSH if thyroid disease is suspected).

At each dose escalation (typically 4-week intervals): Weight, blood pressure, heart rate. Document rate of weight change.

At 3 months and every 6 months thereafter: Full weight and cardiovascular review. If weight loss exceeds 5% of baseline body weight within 3 months, reassess caloric intake and consider a nutrition referral.

In patients with BED specifically: Monitor for compensatory restriction between binge episodes, as lisdexamfetamine-induced appetite suppression during the dosing window may inadvertently worsen an already restrictive dietary pattern outside that window.

Lisdexamfetamine vs. Mixed Amphetamine Salts: A Metabolic Comparison

Mixed amphetamine salts extended-release (Adderall XR) contains both d- and l-amphetamine in a 3:1 ratio. L-amphetamine has a longer half-life but lower potency at the dopamine transporter compared to d-amphetamine. The net metabolic comparison:

• Lisdexamfetamine delivers exclusively d-amphetamine after hydrolysis, producing higher dopamine-to-norepinephrine ratio effects relative to mixed salts at equivalent therapeutic doses.
• Mixed salts XR produces a bimodal release curve (two bead populations), while lisdexamfetamine produces a single smooth curve.
• A head-to-head pharmacokinetic study found that lisdexamfetamine 70 mg produced a d-amphetamine Cmax of approximately 80 ng/mL, while Adderall XR 30 mg (roughly dose-equivalent by response) produced a d-amphetamine Cmax of approximately 50 ng/mL with an earlier Tmax. The higher Cmax from lisdexamfetamine at equivalent doses may translate to more consistent thermogenic activation but also greater cardiovascular exposure.

From a metabolic monitoring standpoint, patients switching from mixed salts to lisdexamfetamine at nominally equivalent doses may experience greater appetite suppression and a longer thermogenic window.

Clinical Guidance Summary for Prescribers

Lisdexamfetamine's metabolic effects are a direct extension of its pharmacological mechanism, not side effects that can be isolated from its therapeutic action. A few specific points for the prescribing clinician:

• Document baseline and follow-up weights at every visit. Use a growth chart for patients under 18.
• Counsel patients about the late-evening appetite rebound and the need for deliberate, nutritionally adequate meals.
• Flag urinary pH-altering supplements (vitamin C megadosing, sodium bicarbonate) and adjust dosing expectations accordingly.
• Apply the eGFR-based dose caps (maximum 50 mg/day for eGFR <30; maximum 30 mg/day for ESRD) without exception.
• Investigate unexpectedly strong thermogenic or cardiovascular responses in new patients with a TSH and consideration of CYP2D6 status.
• The 14-day MAOI washout is non-negotiable.

Patients who lose more than 5% of body weight within the first 12 weeks of therapy at any dose should receive a formal dietary assessment before any further dose escalation is considered.